Mills GB - Search Results

1

Clinical actionability enhanced through deep targeted sequencing of solid tumors.

Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Chen K, et al. Among authors: mills gb. Clin Chem. 2015 Mar;61(3):544-53. doi: 10.1373/clinchem.2014.231100. Epub 2015 Jan 27. Clin Chem. 2015. PMID: 25626406 Free PMC article.

2

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.

Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Koul D, et al. Among authors: mills gb. Oncogene. 2002 Apr 4;21(15):2357-64. doi: 10.1038/sj.onc.1205296. Oncogene. 2002. PMID: 11948419

3

Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.

Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Mansouri A, et al. Among authors: mills gb. J Biol Chem. 2003 May 23;278(21):19245-56. doi: 10.1074/jbc.M208134200. Epub 2003 Mar 12. J Biol Chem. 2003. PMID: 12637505 Free article.

4

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. Knuefermann C, et al. Among authors: mills gb. Oncogene. 2003 May 22;22(21):3205-12. doi: 10.1038/sj.onc.1206394. Oncogene. 2003. PMID: 12761490

5

Molecular therapeutics: promise and challenges.

Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Kohn EC, et al. Among authors: mills gb. Semin Oncol. 2004 Feb;31(1 Suppl 3):39-53. doi: 10.1053/j.seminoncol.2004.01.009. Semin Oncol. 2004. PMID: 15052542 Review.

6

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.

Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Mondesire WH, et al. Among authors: mills gb. Clin Cancer Res. 2004 Oct 15;10(20):7031-42. doi: 10.1158/1078-0432.CCR-04-0361. Clin Cancer Res. 2004. PMID: 15501983

7

Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.

Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F. Dong J, et al. Among authors: mills gb. Cancer Res. 2005 Mar 1;65(5):1961-72. doi: 10.1158/0008-5472.CAN-04-2501. Cancer Res. 2005. PMID: 15753396

8

Mammalian target of rapamycin.

Meric-Bernstam F, Mills GB. Meric-Bernstam F, et al. Among authors: mills gb. Semin Oncol. 2004 Dec;31(6 Suppl 16):10-7; discussion 33. doi: 10.1053/j.seminoncol.2004.10.013. Semin Oncol. 2004. PMID: 15799239 Review.

9

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.

Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Koul D, et al. Among authors: mills gb. Mol Cancer Ther. 2005 Nov;4(11):1681-8. doi: 10.1158/1535-7163.MCT-05-0258. Mol Cancer Ther. 2005. PMID: 16275989

10

BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer.

Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. Rai R, et al. Among authors: mills gb. Cancer Cell. 2006 Aug;10(2):145-57. doi: 10.1016/j.ccr.2006.07.002. Epub 2006 Jul 27. Cancer Cell. 2006. PMID: 16872911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,134 results

Search Page